Iconovo develops novel inhaled products in collaboration with international pharma companies, providing several types of patent-protected inhalers, with significant commercial opportunities in the development of novel products and in patent expirations for established pharmaceuticals.
Iconovo develops novel inhaled pharmaceutical products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers, with significant commercial opportunities in the development of novel pharmaceuticals and in patent expirations for established pharmaceuticals. Iconovo has in-house capabilities in the development of inhalation products – design tools for inhalers, and dry-powder formulation equipment for measuring and mixing, and characterisation testing using next-generation pharmaceutical impactor and high-perfomance liquid chromatography methods. Possessing a unique combination of engineering and pharma expertise, Iconovo can provide the optimal combination of customised inhalers and tailored formulations.
The company was founded in 2013 by Orest Lastow.
It’s stock is publicly traded on the Nasdaq Nordic exchange (STO:ICO).